Akademisyen
CAVİT BOZ
PROFESÖR
KARADENİZ TEKNİK ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.
- Makale 112
- Proje 0
- Kitap 13
- Bildiri 115
- Patent 0
- Sanatsal 0
Scopus (SJR)
Q1
57
Q2
25
Q3
14
Q4
6
WoS (JCR)
Q1
48
Q2
27
Q3
7
Q4
21
TR Index
13
makale
Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.
Üst %1 makale
0
Üst %10 makale
0
Ort. yüzdelik
74.8%
Üst %1 payı
0.0%
Üst %10 payı
0.0%
Makaleler
YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.
Makale listesi
- 2026 Managing reactivation of multiple sclerosis during treatment with natalizumab YÖKSİS SJR Q1 JCR Q1
- 2025 Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study YÖKSİS SJR Q1 JCR Q1
- 2025 Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis YÖKSİS
- 2025 Exome sequencing reveals low-frequency and rare variant contributions to multiple sclerosis susceptibility in Turkish families YÖKSİS
- 2025 Persistent progression independent of relapse activity in multiple sclerosis YÖKSİS
- 2025 Predicting 5-Year EDSS in Multiple Sclerosis with LSTM Networks: A Deep Learning Approach to Disease Progression YÖKSİS SJR Q2 JCR Q3
- 2025 Disease course after pregnancy in women with progressive multiple sclerosis symptoms YÖKSİS SJR Q1 JCR Q1
- 2025 Real-world Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-studyeffectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study YÖKSİS SJR Q1 JCR Q2
- 2025 Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years YÖKSİS SJR Q1 JCR Q1
- 2025 Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG–Positive NMOSD YÖKSİS SJR Q1 JCR Q1
- 2024 Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein YÖKSİS TR Index SJR Q2 JCR Q1
- 2024 Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies YÖKSİS SJR Q1 JCR Q1
- 2024 Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study YÖKSİS SJR Q1 JCR Q1
- 2024 Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries YÖKSİS
- 2024 Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60 YÖKSİS SJR Q1 JCR Q1
- 2024 The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study YÖKSİS SJR Q1 JCR Q1
- 2023 The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COVİD-19 in Multiple Sclerosis YÖKSİS TR Index SJR Q3 JCR Q4
- 2023 Comparative effectiveness in multiple sclerosis: A methodological comparison YÖKSİS SJR Q1 JCR Q1
- 2023 The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COVİD-19 in Multiple Sclerosis YÖKSİS SJR Q3 JCR Q4
- 2023 Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity YÖKSİS SJR Q1 JCR Q2 OpenAlex 64.8%